REPORT ID 18348

Global Biosimilar Therapeutic Antibodies Industry 2016 Market Research Report

Publish Date
2-Jun
Pages
153
Format
Electronic (PDF)

The Global Biosimilar Therapeutic Antibodies Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Biosimilar Therapeutic Antibodies industry.

Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Biosimilar Therapeutic Antibodies market analysis is provided for the international market including development history, competitive landscape analysis, and major regions? development status.

Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin by regions (United States, EU, China and Japan), and other regions can be added.

Then, the report focuses on global major leading industry players with information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What?s more, the Biosimilar Therapeutic Antibodies industry development trends and marketing channels are analyzed.

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

In a word, the report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.


 
			   
Table of Contents

1 Industry Overview of Biosimilar Therapeutic Antibodies
1.1 Definition and Specifications of Biosimilar Therapeutic Antibodies
1.1.1 Definition of Biosimilar Therapeutic Antibodies
1.1.2 Specifications of Biosimilar Therapeutic Antibodies
1.2 Classification of Biosimilar Therapeutic Antibodies
1.3 Applications of Biosimilar Therapeutic Antibodies
1.4 Industry Chain Structure of Biosimilar Therapeutic Antibodies
1.5 Industry Overview and Major Regions Status of Biosimilar Therapeutic Antibodies
1.5.1 Industry Overview of Biosimilar Therapeutic Antibodies
1.5.2 Global Major Regions Status of Biosimilar Therapeutic Antibodies
1.6 Industry Policy Analysis of Biosimilar Therapeutic Antibodies
1.7 Industry News Analysis of Biosimilar Therapeutic Antibodies

2 Manufacturing Cost Structure Analysis of Biosimilar Therapeutic Antibodies
2.1 Raw Material Suppliers and Price Analysis of Biosimilar Therapeutic Antibodies
2.2 Equipment Suppliers and Price Analysis of Biosimilar Therapeutic Antibodies
2.3 Labor Cost Analysis of Biosimilar Therapeutic Antibodies
2.4 Other Costs Analysis of Biosimilar Therapeutic Antibodies
2.5 Manufacturing Cost Structure Analysis of Biosimilar Therapeutic Antibodies
2.6 Manufacturing Process Analysis of Biosimilar Therapeutic Antibodies

3 Technical Data and Manufacturing Plants Analysis of Biosimilar Therapeutic Antibodies
3.1 Capacity and Commercial Production Date of Global Biosimilar Therapeutic Antibodies Major Manufacturers in 2015
3.2 Manufacturing Plants Distribution of Global Biosimilar Therapeutic Antibodies Major Manufacturers in 2015
3.3 R&D Status and Technology Source of Global Biosimilar Therapeutic Antibodies Major Manufacturers in 2015
3.4 Raw Materials Sources Analysis of Global Biosimilar Therapeutic Antibodies Major Manufacturers in 2015

4 Capacity, Production and Revenue Analysis of Biosimilar Therapeutic Antibodies by Regions, Types and Manufacturers
4.1 Global Capacity, Production and Revenue of Biosimilar Therapeutic Antibodies by Regions 2011-2016
4.2 Global and Major Regions Capacity, Production, Revenue and Growth Rate of Biosimilar Therapeutic Antibodies 2011-2016
4.3 Global Capacity, Production and Revenue of Biosimilar Therapeutic Antibodies by Types 2011-2016
4.4 Global Capacity, Production and Revenue of Biosimilar Therapeutic Antibodies by Manufacturers 2011-2016

5 Price, Cost, Gross and Gross Margin Analysis of Biosimilar Therapeutic Antibodies by Regions, Types and Manufacturers
5.1 Price, Cost, Gross and Gross Margin Analysis of Biosimilar Therapeutic Antibodies by Regions 2011-2016
5.2 Price, Cost, Gross and Gross Margin Analysis of Biosimilar Therapeutic Antibodies by Types 2011-2016
5.3 Price, Cost, Gross and Gross Margin Analysis of Biosimilar Therapeutic Antibodies by Manufacturers 2011-2016

6 Consumption Volume, Consumption Value and Sale Price Analysis of Biosimilar Therapeutic Antibodies by Regions, Types and Applications
6.1 Global Consumption Volume and Consumption Value of Biosimilar Therapeutic Antibodies by Regions 2011-2016
6.2 Global and Major Regions Consumption Volume, Consumption Value and Growth Rate of Biosimilar Therapeutic Antibodies 2011-2016
6.3 Global Consumption Volume and Consumption Value of Biosimilar Therapeutic Antibodies by Types 2011-2016
6.4 Global Consumption Volume and Consumption Value of Biosimilar Therapeutic Antibodies by Applications 2011-2016
6.5 Sale Price of Biosimilar Therapeutic Antibodies by Regions 2011-2016
6.6 Sale Price of Biosimilar Therapeutic Antibodies by Types 2011-2016
6.7 Sale Price of Biosimilar Therapeutic Antibodies by Applications 2011-2016
6.8 Market Share Analysis of Biosimilar Therapeutic Antibodies by Different Sale Price Levels

7 Supply, Import, Export and Consumption Analysis of Biosimilar Therapeutic Antibodies
7.1 Supply, Consumption and Gap of Biosimilar Therapeutic Antibodies 2011-2016
7.2 Global Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Biosimilar Therapeutic Antibodies 2011-2016
7.3 USA Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Biosimilar Therapeutic Antibodies 2011-2016
7.4 EU Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Biosimilar Therapeutic Antibodies 2011-2016
7.5 China Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Biosimilar Therapeutic Antibodies 2011-2016
7.6 Japan Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Biosimilar Therapeutic Antibodies 2011-2016

8 Major Manufacturers Analysis of Biosimilar Therapeutic Antibodies
8.1 3SBio (Shenyang Sunshine Pharmaceutical Co)
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.2.1 Type I
8.1.2.2 Type II
8.1.2.3 Type III
8.1.3 Capacity, Production, Price, Cost, Gross and Revenue
8.1.4 Contact Information

8.2 AbbVie
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.2.1 Type I
8.2.2.2 Type II
8.2.2.3 Type III
8.2.3 Capacity, Production, Price, Cost, Gross and Revenue
8.2.4 Contact Information

8.3 AbClon
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.2.1 Type I
8.3.2.2 Type II
8.3.2.3 Type III
8.3.3 Capacity, Production, Price, Cost, Gross and Revenue
8.3.4 Contact Information

8.4 Ablynx
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.2.1 Type I
8.4.2.2 Type II
8.4.2.3 Type III
8.4.3 Capacity, Production, Price, Cost, Gross and Revenue
8.4.4 Contact Information

8.5 AET Biotech
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.2.1 Type I
8.5.2.2 Type II
8.5.2.3 Type III
8.5.3 Capacity, Production, Price, Cost, Gross and Revenue
8.5.4 Contact Information

8.6 Affibody
8.6.1 Company Profile
8.6.2 Product Picture and Specifications
8.6.2.1 Type I
8.6.2.2 Type II
8.6.2.3 Type III
8.6.3 Capacity, Production, Price, Cost, Gross and Revenue
8.6.4 Contact Information

8.7 Affilogic
8.7.1 Company Profile
8.7.2 Product Picture and Specifications
8.7.2.1 Type I
8.7.2.2 Type II
8.7.2.3 Type III
8.7.3 Capacity, Production, Price, Cost, Gross and Revenue
8.7.4 Contact Information

8.8 Affimed Therapeutics
8.8.1 Company Profile
8.8.2 Product Picture and Specifications
8.8.2.1 Type I
8.8.2.2 Type II
8.8.2.3 Type III
8.8.3 Capacity, Production, Price, Cost, Gross and Revenue
8.8.4 Contact Information

8.9 Affitech
8.9.1 Company Profile
8.9.2 Product Picture and Specifications
8.9.2.1 Type I
8.9.2.2 Type II
8.9.2.3 Type III
8.9.3 Capacity, Production, Price, Cost, Gross and Revenue
8.9.4 Contact Information

8.10 Allergan
8.10.1 Company Profile
8.10.2 Product Picture and Specifications
8.10.2.1 Type I
8.10.2.2 Type II
8.10.2.3 Type III
8.10.3 Capacity, Production, Price, Cost, Gross and Revenue
8.10.4 Contact Information

8.11 Baliopharm
8.11.1 Company Profile
8.11.2 Product Picture and Specifications
8.11.2.1 Type I
8.11.2.2 Type II
8.11.2.3 Type III
8.11.3 Capacity, Production, Price, Cost, Gross and Revenue
8.11.4 Contact Information

8.12 Baxalta
8.12.1 Company Profile
8.12.2 Product Picture and Specifications
8.12.2.1 Type I
8.12.2.2 Type II
8.12.2.3 Type III
8.12.3 Capacity, Production, Price, Cost, Gross and Revenue
8.12.4 Contact Information

8.13 Bayer
8.13.1 Company Profile
8.13.2 Product Picture and Specifications
8.13.2.1 Type I
8.13.2.2 Type II
8.13.2.3 Type III
8.13.3 Capacity, Production, Price, Cost, Gross and Revenue
8.13.4 Contact Information

8.14 Binex
8.14.1 Company Profile
8.14.2 Product Picture and Specifications
8.14.2.1 Type I
8.14.2.2 Type II
8.14.2.3 Type III
8.14.3 Capacity, Production, Price, Cost, Gross and Revenue
8.14.4 Contact Information

8.15 Bio Farma
8.15.1 Company Profile
8.15.2 Product Picture and Specifications
8.15.2.1 Type I
8.15.2.2 Type II
8.15.2.3 Type III
8.15.3 Capacity, Production, Price, Cost, Gross and Revenue
8.15.4 Contact Information

8.16 biOasis Technologies
8.16.1 Company Profile
8.16.2 Product Picture and Specifications
8.16.2.1 Type I
8.16.2.2 Type II
8.16.2.3 Type III
8.16.3 Capacity, Production, Price, Cost, Gross and Revenue
8.16.4 Contact Information

8.17 Biocad
8.17.1 Company Profile
8.17.2 Product Picture and Specifications
8.17.2.1 Type I
8.17.2.2 Type II
8.17.2.3 Type III
8.17.3 Capacity, Production, Price, Cost, Gross and Revenue
8.17.4 Contact Information

8.18 BioCND
8.18.1 Company Profile
8.18.2 Product Picture and Specifications
8.18.2.1 Type I
8.18.2.2 Type II
8.18.2.3 Type III
8.18.3 Capacity, Production, Price, Cost, Gross and Revenue
8.18.4 Contact Information

8.19 CytomX Therapeutics
8.19.1 Company Profile
8.19.2 Product Picture and Specifications
8.19.2.1 Type I
8.19.2.2 Type II
8.19.2.3 Type III
8.19.3 Capacity, Production, Price, Cost, Gross and Revenue
8.19.4 Contact Information

8.20 Daewoong Pharmaceutical Co
8.20.1 Company Profile
8.20.2 Product Picture and Specifications
8.20.2.1 Type I
8.20.2.2 Type II
8.20.2.3 Type III
8.20.3 Capacity, Production, Price, Cost, Gross and Revenue
8.20.4 Contact Information

8.21 Daiichi Sankyo
8.21.1 Company Profile
8.21.2 Product Picture and Specifications
8.21.2.1 Type I
8.21.2.2 Type II
8.21.2.3 Type III
8.21.3 Capacity, Production, Price, Cost, Gross and Revenue
8.21.4 Contact Information

9 Marketing Trader or Distributor Analysis of Biosimilar Therapeutic Antibodies
9.1 Marketing Channels Status of Biosimilar Therapeutic Antibodies
9.2 Traders or Distributors with Contact Information of Biosimilar Therapeutic Antibodies by Regions
9.3 Ex-work Price, Channel Price and End Buyer Price Analysis of Biosimilar Therapeutic Antibodies
9.4 Regional Import, Export and Trade Analysis of Biosimilar Therapeutic Antibodies

10 Industry Chain Analysis of Biosimilar Therapeutic Antibodies
10.1 Upstream Major Raw Materials Suppliers Analysis of Biosimilar Therapeutic Antibodies
10.1.1 Major Raw Materials Suppliers with Contact Information Analysis of Biosimilar Therapeutic Antibodies
10.1.2 Major Raw Materials Suppliers with Supply Volume Analysis of Biosimilar Therapeutic Antibodies by Regions
10.2 Upstream Major Equipment Suppliers Analysis of Biosimilar Therapeutic Antibodies
10.2.1 Major Equipment Suppliers with Contact Information Analysis of Biosimilar Therapeutic Antibodies
10.2.2 Major Equipment Suppliers with Product Pictures Analysis of Biosimilar Therapeutic Antibodies by Regions
10.3 Downstream Major Consumers Analysis of Biosimilar Therapeutic Antibodies
10.3.1 Major Consumers with Contact Information Analysis of Biosimilar Therapeutic Antibodies
10.3.2 Major Consumers with Consumption Volume Analysis of Biosimilar Therapeutic Antibodies by Regions
10.4 Supply Chain Relationship Analysis of Biosimilar Therapeutic Antibodies

11 Development Trend of Analysis of Biosimilar Therapeutic Antibodies
11.1 Capacity, Production and Revenue Forecast of Biosimilar Therapeutic Antibodies by Regions and Types
11.1.1 Global Capacity, Production and Revenue of Biosimilar Therapeutic Antibodies by Regions 2016-2021
11.1.2 Global and Major Regions Capacity, Production, Revenue and Growth Rate of Biosimilar Therapeutic Antibodies 2016-2021
11.1.3 Global Capacity, Production and Revenue of Biosimilar Therapeutic Antibodies by Types 2016-2021
11.2 Consumption Volume and Consumption Value Forecast of Biosimilar Therapeutic Antibodies by Regions, Types and Applications
11.2.1 Global Consumption Volume and Consumption Value of Biosimilar Therapeutic Antibodies by Regions 2016-2021
11.2.2 Global and Major Regions Consumption Volume, Consumption Value and Growth Rate of Biosimilar Therapeutic Antibodies 2016-2021
11.2.3 Global Consumption Volume and Consumption Value of Biosimilar Therapeutic Antibodies by Types 2016-2021
11.2.4 Global Consumption Volume and Consumption Value of Biosimilar Therapeutic Antibodies by Applications 2016-2021
11.3 Supply, Import, Export and Consumption Forecast of Biosimilar Therapeutic Antibodies
11.3.1 Supply, Consumption and Gap of Biosimilar Therapeutic Antibodies 2016-2021
11.3.2 Global Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Biosimilar Therapeutic Antibodies 2016-2021
11.3.3 USA Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Biosimilar Therapeutic Antibodies 2016-2021
11.3.4 EU Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Biosimilar Therapeutic Antibodies 2016-2021
11.3.5 China Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Biosimilar Therapeutic Antibodies 2016-2021
11.3.6 Japan Capacity, Production, Price, Cost, Revenue, Supply, Import, Export and Consumption of Biosimilar Therapeutic Antibodies 2016-2021

12 New Project Investment Feasibility Analysis of Biosimilar Therapeutic Antibodies
12.1 New Project SWOT Analysis of Biosimilar Therapeutic Antibodies
12.2 New Project Investment Feasibility Analysis of Biosimilar Therapeutic Antibodies

13 Conclusion of the Global Biosimilar Therapeutic Antibodies Industry 2016 Market Research Report